Financial Performance - The company reported total revenue of HKD 1,007,186,000 for the eighteen months ending June 30, 2022, compared to HKD 567,553,000 for the previous year, representing an increase of approximately 77.4%[5] - Gross profit for the same period was HKD 86,479,000, up from HKD 48,930,000, indicating a growth of about 76.7%[5] - The company incurred a net loss of HKD 5,282,000 for the eighteen months, compared to a profit of HKD 995,000 in the previous year, reflecting a significant decline in profitability[7] - The basic loss per share was HKD 1.40, compared to a loss of HKD 0.49 in the previous year, indicating a worsening financial position[5] - The company reported a total comprehensive loss of HKD 7,034,000 for the period, compared to a comprehensive income of HKD 4,202,000 in the previous year[7] - The company experienced a foreign exchange loss of HKD 1,752,000 from overseas operations, contrasting with a gain of HKD 3,207,000 in the previous year[7] - The company reported a loss attributable to shareholders of approximately HKD 23,531,000 for the period[17] - The group reported a loss of HKD 23,531,000 for the period, compared to a loss of HKD 8,149,000 in the previous year, indicating a year-over-year increase in losses of approximately 188%[30] Expenses and Liabilities - Administrative expenses increased to HKD 39,274,000 from HKD 25,519,000, showing a rise of approximately 54.0%[5] - Sales expenses also rose to HKD 22,679,000 from HKD 12,179,000, marking an increase of about 86.1%[5] - Current liabilities increased from HKD 149,989,000 to HKD 180,354,000, an increase of 20.3%[10] - Non-current liabilities, including convertible bonds, increased from HKD 51,301,000 to HKD 65,650,000, a rise of 27.9%[10] - The total equity position improved from HKD (12,969,000) to HKD 3,243,000, indicating a positive shift in the company's financial health[10] - The company recorded a current tax expense of HKD 3,795,000 for the period, compared to HKD 616,000 in the previous year, indicating a substantial increase of about 516%[28] Assets and Cash Flow - Current assets increased significantly from HKD 90,247,000 to HKD 151,931,000, representing a growth of 68.3% year-over-year[9] - Trade receivables rose from HKD 13,769,000 to HKD 38,386,000, marking an increase of 179.5%[9] - Inventory increased from HKD 52,291,000 to HKD 69,748,000, reflecting a growth of 33.5%[9] - The net current liabilities position improved from HKD (59,742,000) to HKD (28,423,000) indicating a reduction in liabilities[9] - The company's cash and cash equivalents were approximately HKD 7.52 million, an increase from HKD 5.45 million as of December 31, 2020[45] - Total liabilities amounted to approximately HKD 139.57 million, including borrowings of approximately HKD 71.81 million[47] Strategic Initiatives and Future Outlook - The company has not provided specific guidance for future performance or strategic initiatives in the announcement[2] - The company is actively seeking acquisition opportunities to gain new business in the Chinese market and strengthen its revenue and profit base[18] - The company plans to implement measures to improve its working capital and cash flow, including close monitoring of general administrative expenses and operating costs[19] - The company is in discussions with potential investors to raise sufficient funds for its operations[19] - The company has acknowledged the potential need to adjust asset values and liabilities if it cannot continue operations under the going concern basis[18] Audit and Compliance - The financial results were unaudited and subject to further review, indicating potential adjustments in the final audited figures[3] - The company is currently undergoing an audit process for its annual performance, expected to be completed by mid-October 2022[65] - The audited annual results for 2022 will be published by October 31, 2022, and the annual report will be sent to shareholders by mid-November 2022[65] - The financial data for the eighteen-month consolidated annual performance ending June 30, 2022, has not been audited and lacks auditor consent[68] Employee and Operational Information - As of June 30, 2022, the group had a total of 125 employees, primarily working in China[55] - The company is implementing measures to improve its financial situation, including monitoring general administrative expenses and operating costs closely[54] - There were no significant acquisitions or disposals of subsidiaries during the eighteen months ended June 30, 2022[57]
玮俊生物科技(00660) - 2022 Q4 - 年度财报